ISOFOL MEDICAL AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.734 SEK | -0.68% |
|
+0.69% | +0.55% |
| Feb. 20 | Isofol Medical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Feb. 20 | Isofol Medical AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 22.41M 2.05M | Sales 2022 | 12.8M 1.17M | Capitalization | 120M 10.93M |
|---|---|---|---|---|---|
| Net income 2021 | -200M -18.29M | Net income 2022 | -160M -14.63M | EV / Sales 2021 | 49.7 x |
| Net cash position 2021 | 378M 34.54M | Net cash position 2022 | 187M 17.06M | EV / Sales 2022 | -5.24 x |
| P/E ratio 2021 |
-5.8
x | P/E ratio 2022 |
-0.75
x | Employees | 3 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 62.79% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.68% | ||
| 1 week | +0.69% | ||
| Current month | -4.92% | ||
| 1 month | -18.44% | ||
| 3 months | +5.46% | ||
| 6 months | -6.73% | ||
| Current year | +0.55% |
1 week
0.64
1.07
1 month
0.631.07
Current year
0.551.10
1 year
0.451.24
3 years
0.4518.14
5 years
0.4533.50
10 years
0.4533.50
| Managers | Title | Age | Since |
|---|---|---|---|
Petter Lindqvist
CEO | Chief Executive Officer | - | Jan. 08 |
Magnus Hurst
DFI | Director of Finance/CFO | - | Jan. 09 |
Roger Tell
CTO | Chief Tech/Sci/R&D Officer | 59 | 19-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lars Erik Lind
CHM | Chairman | 83 | - |
Sten Nilsson
BRD | Director/Board Member | 76 | Jan. 03 |
Alain Herrera
BRD | Director/Board Member | 74 | 17-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.734 | -0.68% | 526 035 |
| 24-04-18 | 0.739 | +13.69% | 7,113,839 |
| 24-04-17 | 0.65 | -4.27% | 298,790 |
| 24-04-16 | 0.679 | -3.69% | 216,039 |
| 24-04-15 | 0.705 | -3.29% | 274,930 |
Delayed Quote Nasdaq Stockholm, April 19, 2024 at 10:54 am EDT
More quotes
Isofol Medical AB (publ) is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The Company cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Companyâs main shareholders are Biofol AB and Yield Life Science AB.
Sector
Pharmaceuticals
Calendar
2024-05-07
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +0.55% | 10.93M | |
| +10.08% | 9.12B | |
| -17.63% | 4.8B | |
| +0.73% | 3.8B | |
| +16.55% | 3.72B | |
| +27.76% | 2.58B | |
| -26.11% | 2.36B | |
| -30.09% | 2.11B | |
| +7.15% | 1.86B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- ISOFOL Stock
